Conditions: Huntington's Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 37
Healthy volunteers: no

Brief summary:
This study will evaluate the Safety, Tolerability and Brain Function of 2 doses of PF-0254920 in Subjects with Early Huntington's Disease.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None

Interventions: intervention 1: PF-02545920 intervention 2: Placebo intervention 3: PF-02545920 intervention 4: Placebo
Intervention descriptions: intervention 1: * Dose will be titrated up every 2 days by 5mg increments: 5mg Days 1-2, 10mg days 3-4, 15mg days 5-6, and reach 20 mg from Days 7 to Day28.
* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.
* Treatment for 28 days. intervention 2: \- Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.

Dosing for 28 days. intervention 3: * 5mg dose
* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.
* Dosing for 28 days. intervention 4: * Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.
* Dosing for 28 days.

Protocol document: